News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 12, 2023

MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Author(s)Ruben Mesa, M.D., Rami S. Komrokji, M.D.

Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.

Episodes in this series

Experts on MPNs

EP. 1 A Background on Myeloproliferative Neoplasms

Expert on MPNs

EP. 2 How Are Myeloproliferative Neoplasms Diagnosed?

Expert on MPNs

EP. 3 Overview on the Management of Essential Thrombocythemia and Polycythemia Vera

Experts on MPN

EP. 4 Overview of Treatment Options for Myelofibrosis

Expert on MPNs

EP. 5 Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

Expert on MPNs

EP. 6 Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Experts on MPNs

EP. 7 Novel Treatment Strategies in Essential Thrombocythemia and Polycythemia Vera

Expert on MPNs

EP. 8 Myelofibrosis: Novel Treatment Strategies and Combination Therapies

Expert on MPNs

EP. 9 MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Helping You Understand Stage 2 Essential Thrombocythemia

January 25th 2026

The FDA has granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer: © stock.adobe.com.

FDA Orphan Drug Designation Granted to Zavabresib for Myelofibrosis

January 22nd 2026

Image of "FDA"

FDA Accepts Besremi Application for Essential Thrombocythemia

BySpencer Feldman

January 13th 2026

Mayra Andujar-Delgado shares her 10-year myelofibrosis journey and how 2025 Blood Cancer Hero Dr. Faseeh Khaja empowered her and her husband.

A Decade of Patient Proactivity and Physician Partnership

ByMayra Andujar-Delgado

January 11th 2026

Image of blood.

FDA Grants Orphan Drug Designation to CK0804 for Myelofibrosis

BySpencer Feldman

January 9th 2026

Trending on CURE

Tests May Predict Chemo Benefit in Breast Cancer

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

ctDNA Levels May Predict Treatment Response in Advanced Breast Cancer

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma

Beyond Statistics: Lessons in Mindset and Action from a Cancer Survivor